Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Tax Provisions (2016 - 2025)

Historic Tax Provisions for ImmunityBio (IBRX) over the last 10 years, with Q3 2025 value amounting to -$35000.0.

  • ImmunityBio's Tax Provisions changed N/A to -$35000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $31000.0, marking a year-over-year increase of 17750.0%. This contributed to the annual value of -$40000.0 for FY2023, which is 21764.71% down from last year.
  • As of Q3 2025, ImmunityBio's Tax Provisions stood at -$35000.0.
  • In the past 5 years, ImmunityBio's Tax Provisions ranged from a high of $300000.0 in Q2 2025 and a low of -$234000.0 during Q1 2025
  • Over the past 4 years, ImmunityBio's median Tax Provisions value was $1500.0 (recorded in 2021), while the average stood at $4250.0.
  • Its Tax Provisions has fluctuated over the past 5 years, first skyrocketed by 330000.0% in 2022, then crashed by 21764.71% in 2023.
  • Over the past 4 years, ImmunityBio's Tax Provisions (Quarter) stood at $1000.0 in 2021, then soared by 3300.0% to $34000.0 in 2022, then tumbled by 217.65% to -$40000.0 in 2023, then rose by 12.5% to -$35000.0 in 2025.
  • Its Tax Provisions was -$35000.0 in Q3 2025, compared to $300000.0 in Q2 2025 and -$234000.0 in Q1 2025.